Abstract
This study is a retrospective review of all the patients with hepatocellular carcinoma (HCC) who underwent locoregional treatment with ablation therapy only using radiofrequency (RFA) or microwave ablation (MWA) and those treated with combination therapy (ablation plus arterial bland or chemo embolization) for their HCC at the Juravinski Hospital between January 1, 2016 and December 31, 2020. Our aim was to determine if combination therapy was more effective than single modality therapy in preventing residual or recurrent disease after treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
